ELCC 2025 | Professor Gen Lin: Promising Results for Osimertinib Plus Dato-DXd in TKI-Resistant NSCLC from the ORCHARD Study

ELCC 2025 | Professor Gen Lin: Promising Results for Osimertinib Plus Dato-DXd in TKI-Resistant NSCLC from the ORCHARD Study

At the 2025 European Lung Cancer Congress (ELCC), new data from the ORCHARD study were presented, highlighting the potential of osimertinib in combination with Dato-DXd as a post-progression strategy following first-line osimertinib treatment in patients with EGFR-mutant non-small cell lung cancer (NSCLC). This marks the first public release of efficacy and safety findings for this combination in the treatment of EGFR-TKI resistant NSCLC.
ELCC 2025 | Professor Lin Wu: Long-Term Benefit and Individualized Dose Reduction Strategies of Domestic Third-Generation EGFR-TKI in EGFR T790M-Mutated NSCLC

ELCC 2025 | Professor Lin Wu: Long-Term Benefit and Individualized Dose Reduction Strategies of Domestic Third-Generation EGFR-TKI in EGFR T790M-Mutated NSCLC

At the 2025 European Lung Cancer Congress (ELCC), the team led by Professor Lin Wu from the Hunan Cancer Hospital, Xiangya Hospital, Central South University, presented long-term follow-up data on ASK120067 (rezivertinib) in patients with locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer (NSCLC). Oncology Frontier invited Professor Wu to comment on the key findings and clinical implications of the study for our readers.
ELCC 2025| Professor Wei Zhang on the Optimal Duration of Immunotherapy and Novel Strategies Beyond PD-(L)1 Inhibition

ELCC 2025| Professor Wei Zhang on the Optimal Duration of Immunotherapy and Novel Strategies Beyond PD-(L)1 Inhibition

The recently concluded 2025 European Lung Cancer Congress (ELCC) spotlighted several key clinical topics and unveiled new research with strong translational potential. Oncology Frontier invited Professor Wei Zhang of Shanghai Chest Hospital, Shanghai Jiao Tong University for an in-depth interview, where she shared expert insights on the congress's most impactful themes and dissected the scientific highlights shaping the future of lung cancer treatment.
CUDA Yanqi Lake Meeting | Prof. Nianzeng Xing: Advancing Urology in China Through Multidisciplinary Collaboration

CUDA Yanqi Lake Meeting | Prof. Nianzeng Xing: Advancing Urology in China Through Multidisciplinary Collaboration

From April 11 to 13, 2025, the 5th Chinese Urological Doctor Association Yanqi Lake Meeting—jointly organized by the Chinese Medical Doctor Association and Chinese Urological Doctor Association—was successfully held in Beijing. The event brought together prominent experts from across the country to explore the future of urology in China. UroStream invited Professor Nianzeng Xing, President of the Chinese Urological Doctor Association and expert from the Cancer Hospital, Chinese Academy of Medical Sciences, to discuss the meeting highlights, the importance of multidisciplinary collaboration, and efforts to improve care in grassroots hospitals.